Literature DB >> 19432551

Role of the K2 capsule in Escherichia coli urinary tract infection and serum resistance.

Eric L Buckles1, Xiaolin Wang, M Chelsea Lane, C Virginia Lockatell, David E Johnson, David A Rasko, Harry L T Mobley, Michael S Donnenberg.   

Abstract

BACKGROUND: Capsule expression may be important during ascending Escherichia coli urinary tract infections (UTIs).
METHODS: An isogenic ksl(k2)ABCDE mutant of extraintestinal pathogenic E. coli (ExPEC) strain CFT073 that could not synthesize the K2 capsule was compared with wild-type CFT073, to determine virulence in a murine model of ascending UTI and in vitro killing assays.
RESULTS: No significant differences were observed regarding the abilities of the mutant and the wild-type CFT073 strains to colonize the murine urinary tract in single-challenge infection experiments. However, in competitive-colonization experiments, the mutant was significantly outcompeted by the wild-type strain in urine and the kidneys. The mutant strain was also more susceptible to human serum. Complementation of the mutant with a plasmid containing the ksl(k2)ABCDE genes restored capsule expression, enhanced survival in the murine urinary tract, and restored serum resistance.
CONCLUSION: These results indicate that expression of the K2 capsule is important for the pathogenesis of UTI and provides protection against complement-mediated killing. To our knowledge, this is the first study in which the E. coli capsule has been proven to play a role in infection by use of isogenic mutants and genetic complementation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19432551      PMCID: PMC3872369          DOI: 10.1086/598524

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  40 in total

1.  STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III.

Authors:  O T Avery; C M Macleod; M McCarty
Journal:  J Exp Med       Date:  1944-02-01       Impact factor: 14.307

Review 2.  Common themes in microbial pathogenicity.

Authors:  B B Finlay; S Falkow
Journal:  Microbiol Rev       Date:  1989-06

3.  How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains.

Authors:  Elzbieta Brzuszkiewicz; Holger Brüggemann; Heiko Liesegang; Melanie Emmerth; Tobias Olschläger; Gábor Nagy; Kaj Albermann; Christian Wagner; Carmen Buchrieser; Levente Emody; Gerhard Gottschalk; Jörg Hacker; Ulrich Dobrindt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-15       Impact factor: 11.205

4.  The presence of K54 capsular polysaccharide increases the pathogenicity of Escherichia coli in vivo.

Authors:  T A Russo; Y Liang; A S Cross
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

5.  Ongoing horizontal and vertical transmission of virulence genes and papA alleles among Escherichia coli blood isolates from patients with diverse-source bacteremia.

Authors:  J R Johnson; T T O'Bryan; M Kuskowski; J N Maslow
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

6.  Urinary tract infection: self-reported incidence and associated costs.

Authors:  B Foxman; R Barlow; H D'Arcy; B Gillespie; J D Sobel
Journal:  Ann Epidemiol       Date:  2000-11       Impact factor: 3.797

7.  Structure of the Escherichia coli K2 capsular antigen. Stereochemical configuration of the glycerophosphate and distribution of galactopyranosyl and galactofuranosyl residues.

Authors:  W Fischer; M A Schmidt; B Jann; K Jann
Journal:  Biochemistry       Date:  1982-03-16       Impact factor: 3.162

8.  Bacterial virulence versus host resistance in the urinary tracts of mice.

Authors:  C Svanborg-Edén; L Hagberg; R Hull; S Hull; K E Magnusson; L Ohman
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

9.  Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract.

Authors:  I Connell; W Agace; P Klemm; M Schembri; S Mărild; C Svanborg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Identification and characterization of a novel uropathogenic Escherichia coli-associated fimbrial gene cluster.

Authors:  Eric L Buckles; Farah K Bahrani-Mougeot; Anita Molina; C Virgina Lockatell; David E Johnson; Cinthia B Drachenberg; Valerie Burland; Fred R Blattner; Michael S Donnenberg
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

View more
  35 in total

1.  Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization.

Authors:  Meenu Mishra; Matthew S Byrd; Susan Sergeant; Abul K Azad; Matthew R Parsek; Linda McPhail; Larry S Schlesinger; Daniel J Wozniak
Journal:  Cell Microbiol       Date:  2011-11-10       Impact factor: 3.715

2.  Phenotypic heterogeneity enables uropathogenic Escherichia coli to evade killing by antibiotics and serum complement.

Authors:  Marta Putrinš; Karin Kogermann; Eliisa Lukk; Markus Lippus; Vallo Varik; Tanel Tenson
Journal:  Infect Immun       Date:  2015-01-05       Impact factor: 3.441

3.  Optimization of a Noncanonical Anti-infective: Interrogation of the Target Binding Pocket for a Small-Molecule Inhibitor of Escherichia coli Polysaccharide Capsule Expression.

Authors:  Mehreen Arshad; Grace A Beggs; Richard G Brennan; Patrick C Seed
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

4.  Role of the vpe carbohydrate permease in Escherichia coli urovirulence and fitness in vivo.

Authors:  Vanessa Martinez-Jéhanne; Christophe Pichon; Laurence du Merle; Olivier Poupel; Nadège Cayet; Christiane Bouchier; Chantal Le Bouguénec
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

Review 5.  Virulence and Fitness Determinants of Uropathogenic Escherichia coli.

Authors:  Sargurunathan Subashchandrabose; Harry L T Mobley
Journal:  Microbiol Spectr       Date:  2015-08

Review 6.  Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Authors:  Ariel R Brumbaugh; Harry L T Mobley
Journal:  Expert Rev Vaccines       Date:  2012-06       Impact factor: 5.217

7.  Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis.

Authors:  Gregory G Anderson; Carlos C Goller; Sheryl Justice; Scott J Hultgren; Patrick C Seed
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

8.  Dissemination and systemic colonization of uropathogenic Escherichia coli in a murine model of bacteremia.

Authors:  Sara N Smith; Erin C Hagan; M Chelsea Lane; Harry L T Mobley
Journal:  mBio       Date:  2010-11-23       Impact factor: 7.867

Review 9.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

10.  Use of zebrafish to probe the divergent virulence potentials and toxin requirements of extraintestinal pathogenic Escherichia coli.

Authors:  Travis J Wiles; Jean M Bower; Michael J Redd; Matthew A Mulvey
Journal:  PLoS Pathog       Date:  2009-12-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.